Novo Nordisk Launches Recombinant Blood Clotting Factor 8 Formulation In Japan
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk launched Novoeight (turoctocog alfa), a recombinant blood clotting factor 8 formulation to suppress bleeding in hemophilia A patients, in Japan on May 12.